LAS VEGAS, Dec. 31, 2021 /PRNewswire/ -- iMediSync is launching their revolutionary, comprehensive, early mental health diagnostics and remote care solution, iSyncWave™, after 10-years of research and clinical trials.

iMediSync will offer free 10-minute brain screening sessions throughout their press conference and VIP Tour Program at CES 2022. CES attendees can expect a complete analysis report of their measured EEG (brainwaves) and HRV (heart rate variability). In just ten minutes, early signs of multiple mental conditions and impairments of their brains that are not detectable by conventional methods will be analyzed (such as Alzheimer's dementia). Click here to learn more.

When: January 5th at the iMediSync booth and the CES provided conference room on January 6th.

Who should attend: Media, CES attendees interested in AI health technologies, healthcare professionals, researchers, and pharma companies interested in brain reaction to intervention.

More on nvtip.com

• Jacqui Condon Selected to Workers' Compensation Panels for Three Professional Athlete Associations
• New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
• Transformational $104 Million Musculoskeletal Healthcare Opportunity as Expansion Strategy Accelerates for Cardiff Lexington Corp (Stock Symbol: CDIX)
• PropAccount.com Launches Marketing Hub Within PropGenie, Giving Prop Firm Operators an Automated Marketing Team
• Save 15 Percent Off Florida Keys Accommodations with KeysCaribbean's Advance Purchase Rate Discount

Where: Health & Wellness zone, Tech East-North Hall of Las Vegas Convention Center. LVCC, North Hall - 8455. Las Vegas Westgate Resort & Casino. 3000 Paradise Rd, Las Vegas, NV 89109.

ABOUT iMediSync, Inc.

HEADQUARTERED in Seoul, Korea iMediSync was founded by CEO, Dr. Seung Wan Kang. iMediSync has developed an AI-driven early detection and therapeutic platform for optimal brain health. iMediSync launched its first solution to detect Mild Cognitive Impairment (early stage of Alzheimer's Disease) based on its proprietary EEG database in Korea and other parts of the world. Clinical trials with multicenter hospitals confirmed a 90%+ accuracy for its solution. The vision of iMediSync is to develop early-detecting biomarkers for challenging neurological disorders and diseases such as COMA, Parkinson's, ADHD, Depression, etc. For more information, visit www.imedisync.com.

Media Contact:
Photos and interviews can be arranged per your request.

Aditi Maheshwari
(415) 802-4230
[email protected]

SOURCE iMediSync

---

Show All News | Disclaimer | Report Violation